OnKure Therapeutics, Inc.(OKUR) - 2025 Q2 - Quarterly Results

Exhibit 99.1 OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update -- Cash position of $83.4M expected to provide cash runway into Q4 2026 -- PIKture-01, a phase 1 clinical trial assessing OKI-219 in patients with advanced solid tumors, including breast cancer, is on track for single agent and fulvestrant combination data in Q4 2025 -- Initiated a new expansion arm of PIKture-01 to evaluate OKI-219 in combination with fulvestrant and ribociclib in HR+ metastatic br ...